euro adhoc: Marseille-Kliniken AG
Financial Figures/Balance Sheet
- Revenues
increased to EUR 51.5 million in the 1st quarter 2005/2006
- Earnings per share improved EUR 0.31 to EUR 0.54
- 9% bed capacity expansion to 8,169 beds
- Rehabilitation seg
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
07.11.2005
Berlin, November 8, 2005 - Marseille-Kliniken AG (Prime Standard, ISIN DE0007783003, MKA) was able to increase its consolidated operating revenues from EUR 50.8 million to EUR 51.5 million during the first quarter of the current fiscal year (July 1 - September 30, 2005). In accordance with IFRS the earnings pursuant to DVFA/SG remained at previous years level of EUR 3.2 million. Due to the extraordinary effects from the sale-and-lease-back transaction with General Electric the earnings per share rose sharply EUR 0.31 to EUR 0.54.
The trend in revenues and earnings in the first quarter of the fiscal year 2005/2006 was characterized by the expansion of the bed capacity in the Nursing division. Overall, the number of beds within in the Group increased from 7,474 to 8,169. The expansion took place in the Nursing segment exclusively where the number of beds rose by 937 (16%) from 5,723 beds to 6,660 beds. Due to the resulting start-up times the utilization rate amounted to 91.7%, below previous year's rate of 94.8%. Once again revenues were increased from EUR 37.2 million to currently EUR 39.3 million. The earnings pursuant to DVFA remained stable at EUR 3.9 million (previous year EUR 3.9 million).
Although the Rehabilitation segment is still burdened by the overall economic situation, the sustainability of the trend reversal becomes ever clearer. Accordingly, the utilization increased from 75.6% in the previous year to currently 79.2% again. Because of the shut-down of two facilities revenues declined from EUR 13.6 million to EUR 12.2 million as expected. The favorable trend of continuously smaller burdens in the Rehabilitation division becomes visible. The loss was reduced from EUR -0.8 million in the previous year to EUR -0.6 million.
For the current fiscal year ending June 30, 2006 the company expects further growth in revenues as well as an improvement in earnings pursuant to DVFA/SG compared with the past business year.
The detailed Letter to Shareholders for the 1st quarter 2005/2006 is available for download under www.marseille-kliniken.com.
End of ad hoc release
end of announcement euro adhoc 07.11.2005 19:49:10
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Tel.: +49 30 246 32-400
Fax: +49 30 246 32-401
Hillermann Consulting
Christian Hillermann
Tel: +49 40 414 069 13
Fax: +49 40 414 069 14
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: Prime Standard, CDAX, Classic All Share, Prime All Share
Börsen: Berliner Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bremer Wertpapierbörse (BWB) / free trade
Hamburger Wertpapierbörse / official dealing
Frankfurter Wertpapierbörse / official dealing
Original content of: Marseille-Kliniken AG, transmitted by news aktuell